These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21331935)

  • 1. Sarcoma.
    Ceyssens S; Stroobants S
    Methods Mol Biol; 2011; 727():191-203. PubMed ID: 21331935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [18F-FDG-PET-CT in soft tissue sarcomas: when to image?].
    Rodríguez-Alfonso B; Mucientes Rasilla J; Mitjavila Casanovas M; Cardona Arboniés J; Cubedo R
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):43-9. PubMed ID: 24094372
    [No Abstract]   [Full Text] [Related]  

  • 3. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
    Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
    Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-FDG PET-CT in soft tissue sarcomas: staging, restaging, and prognostic value?
    Gabriel M; Rubello D
    Nucl Med Commun; 2016 Jan; 37(1):3-8. PubMed ID: 26457597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization of positron emission tomography in the management of patients with sarcoma.
    Benz MR; Tchekmedyian N; Eilber FC; Federman N; Czernin J; Tap WD
    Curr Opin Oncol; 2009 Jul; 21(4):345-51. PubMed ID: 19412096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of positron emission tomography with fluorine-18-deoxyglucose in the detection of local recurrent and distant metastatic sarcoma.
    Johnson GR; Zhuang H; Khan J; Chiang SB; Alavi A
    Clin Nucl Med; 2003 Oct; 28(10):815-20. PubMed ID: 14508272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography.
    Lucas JD; O'Doherty MJ; Cronin BF; Marsden PK; Lodge MA; McKee PH; Smith MA
    Br J Surg; 1999 Apr; 86(4):550-6. PubMed ID: 10215835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial.
    Völker T; Denecke T; Steffen I; Misch D; Schönberger S; Plotkin M; Ruf J; Furth C; Stöver B; Hautzel H; Henze G; Amthauer H
    J Clin Oncol; 2007 Dec; 25(34):5435-41. PubMed ID: 18048826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical applications of positron emission tomography in sarcoma management.
    Quak E; van de Luijtgaarden AC; de Geus-Oei LF; van der Graaf WT; Oyen WJ
    Expert Rev Anticancer Ther; 2011 Feb; 11(2):195-204. PubMed ID: 21342039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary imaging in sarcoma.
    Landa J; Schwartz LH
    Oncologist; 2009 Oct; 14(10):1021-38. PubMed ID: 19789392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of positron emission tomography in sarcomas.
    Schuetze SM
    Curr Opin Oncol; 2006 Jul; 18(4):369-73. PubMed ID: 16721133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlating metabolic activity on 18F-FDG PET/CT with histopathologic characteristics of osseous and soft-tissue sarcomas: a retrospective review of 136 patients.
    Rakheja R; Makis W; Skamene S; Nahal A; Brimo F; Azoulay L; Assayag J; Turcotte R; Hickeson M
    AJR Am J Roentgenol; 2012 Jun; 198(6):1409-16. PubMed ID: 22623556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular imaging of sarcomas with FDG PET.
    Mendoza H; Nosov A; Pandit-Taskar N
    Skeletal Radiol; 2023 Mar; 52(3):461-475. PubMed ID: 36173459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET for sarcomas other than gastrointestinal stromal tumors.
    Toner GC; Hicks RJ
    Oncologist; 2008; 13 Suppl 2():22-6. PubMed ID: 18434635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. F-18 FDG-PET for detection of osseous metastatic disease and staging, restaging, and monitoring response to therapy of musculoskeletal tumors.
    Peterson JJ
    Semin Musculoskelet Radiol; 2007 Sep; 11(3):246-60. PubMed ID: 18260035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of 18F fluorodeoxyglucose positron emission tomography/computed tomography in staging of pediatric sarcomas.
    Tateishi U; Hosono A; Makimoto A; Sakurada A; Terauchi T; Arai Y; Imai Y; Kim EE
    J Pediatr Hematol Oncol; 2007 Sep; 29(9):608-12. PubMed ID: 17805034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of fluorine-18 fluorodesoxyglycose-positron emission tomography for treatment monitoring in patients with soft tissue sarcomas.
    Kasper B; Hohenberger P; Strauss LG; Dimitrakopoulou-Strauss A
    Hell J Nucl Med; 2010; 13(1):40-4. PubMed ID: 20411170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intense accumulation of 18F-FDG, not enhancement on MRI, helps to guide the surgical biopsy accurately in soft tissue tumors.
    Park JH; Park EK; Kang CH; Kim CH; Choe JG; Noh W
    Ann Nucl Med; 2009 Dec; 23(10):887-9. PubMed ID: 19862481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging in sarcoma.
    Eary JF; Conrad EU
    J Nucl Med; 2011 Dec; 52(12):1903-13. PubMed ID: 22052127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.